Repository corticotropin (Acthar Gel)
Peptide
Evidence outlook
Approved: Multiple Sclerosis, Psoriatic Arthritis, Epilepsy, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis Exacerbations, Dermatomyositis, Idiopathic Inflammatory Myopathies, Non-Infectious Uveitis, Lupus Nephritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02290444 NCT02290444 · Multiple Sclerosis The study was nonrandomized and unblinded, and its comparison group received no intervention rather than placebo or active treatment. Although 25 participants per group were included in the reported primary analyses, the registry provides no statistical tests showing that any of the five primary cognitive or walking outcomes was met. Registry: NCT02290444 | 3 | Change From Baseline on the Symbol Digit Modalities Test (SDMT) (Day 0 and Day 90); Timed 25-foot Walk (Day 0 and Day 90); Change From Baseline on the Paced Auditory Serial Addition Test (PASAT) (Day 0 and Day 90); Change From Baseline on the Brief Visuospatial Memory Test-Revised (BVMT-R) (Day 0 and Day 90); Change From Baseline on the California Verbal Learning Test, Second Edition (CVLT-II) (Day 0 and Day 90) 2018-11-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
View 1 more trial
NCT02315872 NCT02315872 · Multiple Sclerosis, Relapsing-Remitting Although this trial was randomized and triple-blinded with a placebo comparator, it enrolled only 8 participants (4 per arm), which is severely underpowered for any meaningful primary-endpoint comparison. The reported fatigue scores at 28 weeks were actually numerically worse, not better, in the ACTH group compared to placebo, and no statistical test was reported to interpret this difference, so the design's blinding and randomization cannot compensate for the tiny sample size. Registry: NCT02315872 | 3 | Fatigue at 28 Weeks 2017-06-20 | Fatigue at 28 Weeks (28 weeks): ACTH — MFIS: 56.5 score on a scale (range 21 to 74); FSS: 55 score on a scale (range 25 to 63) | Placebo — MFIS: 29 score on a scale (range 5 to 74); FSS: 40 score on a scale (range 25 to 57) | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (48)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2/3 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Dermatomyositis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Repository Corticotropin (Acthar Gel): this drug | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-06823859 | Phase 3 | Monoclonal antibody | Interferon beta (IFN-beta) | not yet graded | No reviewed efficacy summary in this indication | |
| Descartes-08 | Phase 1/2 | Cell therapy | BCMA (B-cell maturation antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| Cadefrecitinib | Discontinued | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Repository corticotropin (Acthar Gel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.